Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Sven Turkalj"'
Publikováno v:
STAR Protocols, Vol 4, Iss 4, Pp 102641- (2023)
Summary: Single-cell assay for transposase-accessible chromatin with sequencing (scATAC-seq) resolves the heterogeneity of epigenetic states across cells but does not typically capture exonic mutations, which limits our knowledge of how somatic mutat
Externí odkaz:
https://doaj.org/article/74639132d5b741ccbc93ab653e811900
Publikováno v:
HemaSphere, Vol 7, Iss 6, p e914 (2023)
Acute myeloid leukemia (AML) is the most aggressive adult leukemia, characterized by clonal differentiation arrest of progenitor or precursor hematopoietic cells. Intense preclinical and clinical research has led to regulatory approval of several tar
Externí odkaz:
https://doaj.org/article/0dc4689a331a427bb2fab8c88e7c5729
Autor:
Curtis A. Lachowiez, Sanam Loghavi, Zhihong Zeng, Tomoyuki Tanaka, Yi June Kim, Hidetaka Uryu, Sven Turkalj, Niels Asger Jakobsen, Marlise R. Luskin, Dzifa Y. Duose, Rebecca S S. Tidwell, Nicholas J. Short, Gautam Borthakur, Tapan M. Kadia, Lucia Masarova, George D. Tippett, Prithviraj Bose, Elias J. Jabbour, Farhad Ravandi, Naval G. Daver, Guillermo Garcia-Manero, Hagop Kantarjian, Jacqueline S. Garcia, Paresh Vyas, Koichi Takahashi, Marina Konopleva, Courtney D. DiNardo
Publikováno v:
Blood Cancer Discovery.
The safety and efficacy of combining the IDH1 inhibitor ivosidenib (IVO) with the BCL2 inhibitor venetoclax (VEN; IVO+VEN) +/- azacitidine (AZA; IVO+VEN+AZA) was evaluated in four cohorts of patients with IDH1-mutated myeloid malignancies (n=31). Mos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a2ef2e5e66589607245ebefd8e9103d
https://doi.org/10.1158/2643-3230.bcd-22-0205
https://doi.org/10.1158/2643-3230.bcd-22-0205
Autor:
Sven Turkalj, Niels Asger Jakobsen, Angus Groom, Marlen Metzner, Batchimeg Usukhbayar, Mirian Angulo Salazar, Kevin Clark, E. Ravza Gür, Lance D. Hentges, Paul Sopp, James O.J. Davies, Jim R. Hughes, Paresh Vyas
Publikováno v:
Blood. 140:1193-1194
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c8ab0bfff0faeef08a8a1256eae3e7c3
https://doi.org/10.1182/blood-2022-163139
https://doi.org/10.1182/blood-2022-163139
Publikováno v:
Cancers
Cancers, Vol 12, Iss 1396, p 1396 (2020)
Cancers, Vol 12, Iss 1396, p 1396 (2020)
The B cell receptor (BCR) pathway has been identified as a potential therapeutic target in a number of common B cell malignancies, including chronic lymphocytic leukemia, diffuse large B cell lymphoma, Burkitt lymphoma, follicular lymphoma, mantle ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3f218b65489a23d4380b3db9064c814
https://pubmed.ncbi.nlm.nih.gov/32481736
https://pubmed.ncbi.nlm.nih.gov/32481736
Autor:
Claudio Martines, Malgorzata Bobrowicz, Sven Turkalj, Beata Pyrzynska, Joanna Stachura, Binu K. Sasi, Engin Bojnik, Francesco Bertoni, Dimitar G. Efremov, Magdalena Winiarska, Richard Rosenquist, Elena Xerxa, Hilal Kalkan, Larry Mansouri, Valdemar Priebe, Fabiola Porro, Rosa Fazio, Abdessamad Zerrouqi
Publikováno v:
Leukemia. 33(10)
The BCL-2 inhibitor venetoclax has only limited activity in DLBCL despite frequent BCL-2 overexpression. Since constitutive activation of the B cell receptor (BCR) pathway has been reported in both ABC and GCB DLBCL, we investigated whether targeting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c8ee0c29e9fa452d48dd21bf19da2a2d
https://pubmed.ncbi.nlm.nih.gov/30872780
https://pubmed.ncbi.nlm.nih.gov/30872780
Autor:
Fabiola Porro, Engin Bojnik, Francesco Bertoni, Binu K. Sasi, Beata Pyrzynska, Abdessamad Zerrouqi, Richard Rosenquist, Dimitar G. Efremov, Magdalena Winiarska, Malgorzata Bobrowicz, Sven Turkalj, Valdemar Priebe, Hilal Kalkan, Larry Mansouri
Publikováno v:
Blood. 132:2860-2860
Functional and transcriptional profiling studies have identified a subset of diffuse large B cell lymphoma (DLBCL) tumors that rely on B cell receptor (BCR) signals for proliferation and survival. These BCR-dependent tumors have been identified among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6c35d2eed41603cce83b578c09c1451e
https://doi.org/10.1182/blood-2018-99-118120
https://doi.org/10.1182/blood-2018-99-118120